Evaluating ianalumab with corticosteroids for treating primary immune thrombocytopenia
Official title: A Phase III, Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (VAYHIT1)
Run by Novartis · NCT05653349 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study is testing if a new drug called ianalumab can help adults with primary immune thrombocytopenia maintain healthy platelet levels when used with standard corticosteroids.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 100 Years |
| Sex | All |
| Enrollment | 225 (estimated) |
| Sponsor | Novartis Industry-sponsored |
| Drugs / interventions | rituximab, ianalumab |
| Locations | 152 sites (Yuma, Arizona and 151 other locations) |
| Trial ID | NCT05653349 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older diagnosed with primary ITP within the last three months and having a platelet count below 30 G/L.
✕Probably not a fit
Patients with Evans syndrome, life-threatening bleeding, or those who have previously undergone ITP treatments other than corticosteroids or IVIG may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This Phase 3 clinical trial investigates the efficacy and safety of two doses of ianalumab compared to a placebo in adult patients with primary immune thrombocytopenia (ITP) who are receiving first-line corticosteroid treatment. Participants will be randomly assigned to receive either ianalumab or placebo alongside standard corticosteroids, with the primary goal of maintaining a platelet count of at least 30 G/L. The study will include a screening period followed by a treatment phase, and participants will be monitored for efficacy and safety outcomes during a follow-up period.
Why it matters
Potential benefit: If successful, this treatment could provide a new therapeutic option for patients with primary immune thrombocytopenia, potentially improving platelet counts and reducing the need for more invasive treatments.
How similar studies have gone: Other studies have shown promising results with similar approaches targeting B-cell depletion in ITP, suggesting potential for success in this trial.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Signed informed consent prior to participation in the study. * Male or female participants aged 18 years and older on the day of signing informed consent * Primary ITP diagnosed within 3 months before initiating first-line ITP therapy (corticosteroids, IVIG) * Platelet count below 30 G/L before starting any first-line ITP therapy (corticosteroids, IVIG) * Response (platelet count \>=50 G/L) to corticosteroids (+/- IVIG) at any time prior to randomization. Note: Platelet count measured within 7 days of platelet transfusion will not be considered as response. Key Exclusion Criteria: * Evans syndrome or any other cytopenia (patients with low grade anemia related to bleeding or iron deficiency are eligible) * Current life-threatening bleeding * Previous ITP treatment, including splenectomy, except for corticosteroids and/or IVIG initiated as first-line therapy for up to 28 days before randomization and rescue corticosteroids and/or IVIG given prior to confirmed diagnosis of primary ITP . * Prior use of B-cell depleting therapy (e.g., rituximab). * Absolute neutrophil count below 1.0 G/L at randomization * Participants with concurrent coagulation disorders and/or receiving anti-platelet or anticoagulant medication with an exemption of low dose of acetylsalicylic acid Other protocol-defined Inclusion/Exclusion may apply.
Where it's running
-
Yuma Regional Medical Center
Yuma, Arizona, United States Recruiting -
Community Cancer Institute
Clovis, California, United States Recruiting -
Compassionate Care Res Group Inc
Fountain Valley, California, United States Recruiting -
University of Colorado Anschutz
Aurora, Colorado, United States Recruiting -
Napa Research
Margate, Florida, United States Recruiting -
Uni of Chi Medi Ctr Hema and Onco
Chicago, Illinois, United States Recruiting
Show 44 more locations
-
Oncology Care Associates
Bethesda, Maryland, United States Recruiting -
Massachusetts General Hospital
Boston, Massachusetts, United States Recruiting -
Michigan Center of Medical Research
Farmington Hills, Michigan, United States Recruiting -
Mayo Clinic Rochester
Rochester, Minnesota, United States Recruiting -
Metro Minnesota CCOP
Saint Louis Park, Minnesota, United States Recruiting -
St Vincent Frontier Cancer Center
Billings, Montana, United States Recruiting -
Inspira Medical Cent Mullica Hill
Mullica Hill, New Jersey, United States Recruiting -
Clinical Research Alliance
Lake Success, New York, United States Recruiting -
Hematology Oncology Association of Rockland
Nyack, New York, United States Recruiting -
Cleveland Clinic Foundation
Cleveland, Ohio, United States Recruiting -
STAT Research Inc
Dayton, Ohio, United States Recruiting -
INTEGRIS Cancer Institute of Oklahoma
Oklahoma City, Oklahoma, United States Recruiting -
University of Pennsylvania
Philadelphia, Pennsylvania, United States Recruiting -
Rhode Island Hospital
Providence, Rhode Island, United States Recruiting -
Texas Oncology-Baylor Res Ins
Dallas, Texas, United States Recruiting -
Texas Oncology
McAllen, Texas, United States Recruiting -
Mays Cancer Ctr Uthsa Mdacc
San Antonio, Texas, United States Recruiting -
Community Cancer Trials of Utah
Ogden, Utah, United States Recruiting -
Novartis Investigative Site
Bahia Blanca, Buenos Aires, Argentina Recruiting -
Novartis Investigative Site
Caba, Buenos Aires, Argentina Recruiting -
Novartis Investigative Site
Caba, Buenos Aires, Argentina Recruiting -
Novartis Investigative Site
Ciudad Autonoma de Bs As, Buenos Aires, Argentina Recruiting -
Novartis Investigative Site
Tucuman, San Miguel De Tucuman, Argentina Recruiting -
Novartis Investigative Site
Buenos aires, Argentina Recruiting -
Novartis Investigative Site
Cordoba, Argentina Recruiting -
Novartis Investigative Site
Canberra, Australian Capital Territory, Australia Recruiting -
Novartis Investigative Site
Wooloongabba, Queensland, Australia Recruiting -
Novartis Investigative Site
Clayton, Victoria, Australia Recruiting -
Novartis Investigative Site
Melbourne, Victoria, Australia Recruiting -
Novartis Investigative Site
Innsbruck, Tyrol, Austria Recruiting -
Novartis Investigative Site
Wien, Austria Recruiting -
Novartis Investigative Site
Brasschaat, Belgium Recruiting -
Novartis Investigative Site
Brugge, Belgium Recruiting -
Novartis Investigative Site
Leuven, Belgium Recruiting -
Novartis Investigative Site
Roeselare, Belgium Recruiting -
Novartis Investigative Site
Plovdiv, Bulgaria Recruiting -
Novartis Investigative Site
Sofia, Bulgaria Recruiting -
Novartis Investigative Site
Sofia, Bulgaria Recruiting -
Novartis Investigative Site
Beijing, Beijing, China Recruiting -
Novartis Investigative Site
Chongqing, Chongqing, China Recruiting -
Novartis Investigative Site
Guangzhou, Guangdong, China Recruiting -
Novartis Investigative Site
Shenzhen, Guangdong, China Recruiting -
Novartis Investigative Site
Luoyang, Henan, China Recruiting -
Novartis Investigative Site
Zhengzhou, Henan, China Recruiting
+102 more sites. See ClinicalTrials.gov for the full list.
Study contacts
- Study coordinator: Novartis Pharmaceuticals
- Email: novartis.email@novartis.com
- Phone: 1-888-669-6682
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Ianalumab plus a thrombopoietin receptor agonist for adults with ITP or Evans syndrome
This study will test whether adding ianalumab to a doctor's chosen TPO-RA is tolerable for adults with immune thrombocytopenia (and an exploratory group with Evans syndrome) who have had prior treatments and are on a stable TPO-RA dose.
-
Ianalumab vs placebo in adults with Sjögren's disease and high symptom burden
A 52-week study will test whether monthly 300 mg ianalumab injections help adults with Sjögren's disease who have high symptom burden.
-
High-dose dexamethasone plus orelabrutinib versus placebo for newly diagnosed adult ITP
This trial tests whether adding orelabrutinib to high-dose dexamethasone helps adults newly diagnosed with primary ITP raise and maintain their platelet counts compared with placebo.
-
Intravenous immunoglobulin (5%) treatment for primary immune thrombocytopenia
This study tests whether 5% intravenous immunoglobulin given daily for five days safely raises platelet counts in adults (18–65) with chronic primary ITP and platelet counts below 30 × 10^9/L.
-
Romiplostim combined with glucocorticoids for treating newly diagnosed adult ITP
This study is testing if a new treatment combining romiplostim and glucocorticoids can help adults newly diagnosed with immune thrombocytopenia feel better compared to just using glucocorticoids alone.
-
Testing STSA-1301 injection for treating immune thrombocytopenia
This study is testing a new injection called STSA-1301 to see if it can safely help people with immune thrombocytopenia improve their platelet levels.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.